Professional
Added to YB: 2025-02-18
Pitch date: 2025-02-17
HROW [bullish]
Harrow, Inc.
+14.99%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.3B
Pitch Price
$30.55
Price Target
122.00 (+247%)
Dividend
N/A
EV/EBITDA
29.74
P/E
-253.44
EV/Sales
5.49
Sector
Pharmaceuticals
Category
growth
Generation PMCA Portfolio Holding: Harrow, Inc.
HROW: Ophthalmic pharma co. w/ 17 eye therapies. New drugs IHEEZO (ocular anesthetic gel, 82% reorder) & VEVYE (water-free cyclosporine, 92% refill) to boost sales. $1.1B mkt cap. Mgmt guides $1B rev by 2027 (~$300M earnings). FMV est. 4x current price. Risks: new profitability, competition, sales team execution.
Read full article (1 min)